InfuSystem (NYSEAM:INFU) Q4 2025 Earnings call February 24, 2026 09:00 AM ET Company ParticipantsBarry Steele - CFOCarrie Lachance - President and CEOGlen Akselrod - President and FounderConference Call ParticipantsAnderson Schock - MedTech Equity Research AnalystBenjamin Haynor - Managing Director and Senior Research AnalystJames Sidoti - Senior Equity Research AnalystKyle Bauser - Managing Director and Senior Research AnalystTollef Kohrman - Equity Research AnalystOperatorPlease note, this event is being ...

Group 1 - The core point of the news is that southbound funds have reduced their holdings in Baize Medical (02609.HK) by 142.44 million shares on December 11, 2025, marking a total net reduction of 204.06 million shares over the last five trading days [1][2] - Over the past 20 trading days, southbound funds have reduced their holdings in Baize Medical on 10 occasions, resulting in a cumulative net reduction of 271.32 million shares [1][2] - As of now, southbound funds hold 60.83 million shares of Baize Medical, which accounts for 4.6% of the company's total issued ordinary shares [1][2] Group 2 - Baize Medical Group is primarily engaged in investment and provision of medical-related services, focusing on oncology medical services [2] - The company offers comprehensive oncology services, including screening, diagnosis, treatment, and rehabilitation, and operates mainly in the Chinese market [2]